RecruitingNot ApplicableNCT06534125

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Preventing Aromatase Inhibitor-Associated Arthralgias Among Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer


Sponsor

Emory University

Enrollment

150 participants

Start Date

Dec 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor positive (HR+) breast cancer. Aromatase inhibitors (AI) are medications that prevent the formation of the hormone estrogen. They are used in the treatment of postmenopausal women who have hormone-dependent breast cancer. AI therapy prolongs life among patients with early-stage HR+ breast cancer. Many postmenopausal women stop AI therapy early due to debilitating joint pain (arthralgias). Non-Hispanic Black women are more likely to experience side effects and stop their hormonal therapy compared to Non-Hispanic white women. Acupuncture therapy involves inserting thin needles through the skin at specific points on the body to control pain. Acupressure therapy uses the application of pressure or localized massage to specific sites on the body to control symptoms such as pain. Acupuncture and acupressure are types of complementary and alternative medicine. Undergoing in-person acupuncture or participating in virtual acupressure may prevent AI-associated arthralgias (AIAA) in Non-Hispanic Black postmenopausal women with early-stage HR+ breast cancer.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether acupuncture can prevent or reduce joint pain (called aromatase inhibitor-associated arthralgias) in Non-Hispanic Black postmenopausal women with early-stage breast cancer who are starting aromatase inhibitor (AI) therapy. AIs are hormone-blocking pills used to reduce the risk of breast cancer returning, but they commonly cause joint and muscle pain that leads many women to stop taking them. This study focuses on a group that is underrepresented in cancer research. **You may be eligible if...** - You are 18 or older and self-identify as a Non-Hispanic Black woman - You are postmenopausal - You have been diagnosed with Stage I-III hormone receptor-positive (HR+), HER2-negative breast cancer - You have completed surgery, chemotherapy, and/or radiation - You are about to start adjuvant AI therapy (like letrozole, anastrozole, or exemestane) **You may NOT be eligible if...** - You have metastatic (stage IV) breast cancer - You are premenopausal - You have already taken an AI for more than 14 days - You have received acupuncture within the last 60 days - You have rheumatoid arthritis, multiple sclerosis, or muscular dystrophy - You have taken or are taking a CDK 4/6 inhibitor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREAcupressure Therapy

Undergo self-administered acupressure therapy to planned pressure points

DEVICEAcupuncture Therapy

Undergo acupuncture therapy with acupuncture needles applied to planned pressure points

DRUGAromatase Inhibition Therapy

Receive SOC AI therapy

OTHERDiscussion

Ancillary studies

OTHERSurvey Administration

Ancillary studies


Locations(4)

Grady Health System

Atlanta, Georgia, United States

Emory University Hospital Midtown

Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States

Emory Saint Joseph's Hospital

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06534125


Related Trials